LL-37 for Wound Healing: Tissue Repair Research Reviewed
Published research on LL-37 for wound healing points to a peptide that acts on multiple repair pathways at once — re-epithelialization, angiogenesis, keratinocyte migration, and broad-spectrum antimicrobial defense. This guide curates the fragmented cathelicidin literature into one evidence-based research reference.
What Is LL-37? The Human Cathelicidin Behind Tissue Repair Research
LL-37 is the only known human cathelicidin antimicrobial peptide, derived from the C-terminal cleavage of the hCAP-18 precursor protein and named for its two N-terminal leucine residues across a 37-amino-acid sequence. Research on LL-37 for wound healing has expanded steadily since the early 2000s, when investigators first noted that this cationic, amphipathic defense peptide regulates far more than just bacterial killing. A 2003 Journal of Investigative Dermatology study (PMID: 12713579) demonstrated that LL-37 expression is markedly upregulated at wound edges in human skin and that its absence correlates with chronic, non-healing ulcers.
As a host defense peptide, LL-37 sits at the intersection of innate immunity and tissue regeneration. It chemoattracts human peripheral blood neutrophils, modulates macrophage polarization, and stimulates epithelial cell migration — activities documented across in vitro and in vivo models. The National Institutes of Health PMC archive catalogues hundreds of cathelicidin studies spanning antimicrobial activity against gram-positive and gram-negative bacteria, biofilm disruption, immune activation, and direct effects on keratinocyte and endothelial cells. This dual antimicrobial-regenerative profile is what makes LL-37 a sustained research target in skin repair biology.
How LL-37 for Wound Healing Works: Core Mechanisms of Tissue Repair
Research suggests LL-37 promotes wound healing through at least four overlapping mechanisms: direct antimicrobial defense, keratinocyte activation and migration, angiogenesis induction, and immunomodulatory signaling. Each pathway has been characterized in separate preclinical models, and the integrated picture explains why this single defense peptide influences such a broad slice of repair biology.
Receptor Engagement and Cell Activation
LL-37 binds multiple cell-surface receptors, including formyl peptide receptor-like 1 (FPRL1/FPR2), the EGFR axis on keratinocytes, and pattern-recognition receptors such as toll-like receptor 4. A 2009 review in the Journal of Biological Chemistry details how this receptor promiscuity allows LL-37 to coordinate chemotaxis, gene expression changes, and downstream cytokine release across multiple immune and epithelial cell types simultaneously.
Membrane Interaction and Antimicrobial Action
The peptide’s amphipathic alpha-helical structure preferentially targets anionic bacterial membranes over zwitterionic mammalian cell membranes. Studies indicate that membrane disruption proceeds via the “carpet” model at high concentrations and via toroidal pore formation at lower ones, producing broad-spectrum antimicrobial activity against both gram-positive and gram-negative bacteria as well as several enveloped pathogens.
Research Insight: Concentration-Dependent Behavior
Preclinical and clinical data show LL-37 exhibits sharply concentration-dependent effects. At sub-micromolar levels it functions primarily as an immunomodulator and migration signal; at higher concentrations its antimicrobial and membrane-disrupting activities dominate. Studies utilized doses across this entire range to map dual function.
Why This Matters for Tissue Repair Models
Because the same peptide drives both antimicrobial and regenerative activity, researchers can study LL-37 in wound healing models without separating “infection control” from “tissue rebuild” experimentally. Research subjects received LL-37 across in vitro scratch assays, ex vivo human skin explants, and murine excisional wound models, with consistent reports of accelerated wound closure relative to vehicle controls. This consistency across systems is what has elevated LL-37 from a curiosity to a sustained tissue regeneration research target.
LL-37 Re-Epithelialization and Keratinocyte Migration
Re-epithelialization — the resurfacing of a wound by migrating and proliferating keratinocytes — is the rate-limiting step in many chronic wound models. Preclinical and clinical data show that LL-37 directly stimulates this process at concentrations within its physiologic range at wound sites.
Keratinocyte Migration in Scratch Assays
A 2008 study (PMID: 18408746) reported that LL-37 stimulated keratinocyte migration in scratch-wound assays via transactivation of the epidermal growth factor receptor. The effect was dose-dependent and abolished by EGFR kinase inhibitors, establishing a defined signaling pathway linking the antimicrobial peptide to epithelial repair.
Effects on Gene Expression and Proliferation
Beyond migration, LL-37 alters gene expression in keratinocytes — upregulating transcripts associated with proliferation, cytokine release, and extracellular matrix remodeling. Studies indicate that this transcriptional reprogramming, combined with the peptide’s chemotactic signaling, may explain why topical application in animal models accelerates wound closure even in the absence of overt infection.
Ex Vivo and In Vivo Confirmation
Findings from scratch assays have been corroborated in ex vivo human skin explants and murine excisional wound models. Across these systems, LL-37 treatment produced earlier and more complete re-epithelialization than vehicle controls, with the largest effect sizes observed when application was timed to early inflammatory phases of repair.
LL-37 Angiogenesis: Vascular Tissue Regeneration Research
Angiogenesis — the formation of new blood vessels from existing vasculature — is essential for granulation tissue formation and sustained wound repair. Research indicates LL-37 functions as a direct angiogenic factor in addition to its antimicrobial and epithelial roles.
Endothelial Cell Activation
A foundational 2003 study in the Journal of Clinical Investigation (PMID: 12714512) demonstrated that LL-37 directly induces proliferation, migration, and tube formation in human endothelial cells. The effect was mediated through FPRL1 receptor binding and persisted across multiple in vitro angiogenesis assays, suggesting the peptide acts as a genuine pro-angiogenic signal rather than a downstream consequence of inflammation.
Key Research Finding: In Vivo Confirmation
In rabbit hindlimb ischemia and chick chorioallantoic membrane models, LL-37 administration increased neovascularization compared to controls. This in vivo confirmation strengthened the case that cathelicidin-driven angiogenesis is a real biological phenomenon and not an in vitro artifact.
Crosstalk with VEGF and FGF Pathways
Subsequent research has clarified that LL-37 angiogenic activity partially overlaps with — but is not entirely dependent on — VEGF and FGF signaling. The peptide can drive endothelial activation directly through FPRL1 and indirectly by upregulating VEGF expression in nearby cells, creating a self-reinforcing pro-angiogenic microenvironment within healing tissue.
Antimicrobial and Anti-Biofilm Activity at Wound Sites
Although the regenerative effects of LL-37 are central to wound healing research, its broad-spectrum antimicrobial activity remains the foundation of its host defense function. Studies indicate the peptide retains activity against bacteria that have acquired resistance to conventional antibiotics — a feature that has prompted sustained interest from translational researchers.
Spectrum of Activity
LL-37 demonstrates broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, including Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli — three of the most common human bacterial pathogens isolated from chronic wound beds.
Anti-Biofilm Properties
A 2015 PMC review on antimicrobial peptide wound healing applications consolidated evidence that LL-37 prevents biofilm formation and degrades preformed biofilms at sub-MIC concentrations. Because biofilm presence is a defining feature of hard-to-heal venous leg ulcers and diabetic foot ulcers, this anti-biofilm activity is one of the most clinically relevant attributes of the peptide.
Clinical Trial Context
A registered clinical trial on ClinicalTrials.gov and a published phase I/II study (Grönberg et al., 2014) examined LL-37 in patients with hard-to-heal venous leg ulcers. Research subjects received different concentrations of the peptide, and the study reported tolerability with signals of accelerated healing of hard-to-heal venous leg ulcers at certain doses. These early-phase data inform — but do not establish — therapeutic application; additional research is required.
⚠️ 5 Important Research Considerations for LL-37 for Wound Healing
Interpreting LL-37 wound healing data accurately requires accounting for the peptide’s complex biology and the experimental conditions under which it has been studied.
- Concentration windows matter. LL-37 displays biphasic behavior: regenerative at low concentrations, cytotoxic and pro-inflammatory at high concentrations. Findings from one dose range do not generalize across the full curve.
- Serum and salt sensitivity. Antimicrobial activity is partially suppressed by physiologic salt concentrations and by binding to serum components, which complicates extrapolation from in vitro buffers to in vivo wound environments.
- Protease degradation in chronic wounds. Chronic wound fluid contains elevated proteases that rapidly degrade unprotected LL-37, limiting native peptide bioavailability and making formulation a critical variable in study design.
- Dual antimicrobial-immunomodulatory role. LL-37 can both dampen and amplify inflammatory signaling depending on context. Honest interpretation requires acknowledging this bidirectional immunomodulatory profile.
- Species and model variability. Findings in murine excisional models, porcine skin, ex vivo human explants, and primary keratinocyte cultures do not always converge — model choice substantially shapes outcomes.
Issue: Buffer-only in vitro testing → Research Impact: Overestimates antimicrobial potency vs. wound-bed physiologic conditions.
Issue: Single concentration tested → Research Impact: Misses the regenerative-to-cytotoxic inflection point of the dose-response curve.
Understanding these limitations is critical for interpreting LL-37 for wound healing research accurately and for designing reproducible follow-on studies.
✅ What the Research Shows About LL-37 for Wound Healing
These principles emerge consistently across more than two decades of cathelicidin literature and represent the current research consensus on LL-37 tissue repair biology.
Research backing for these principles is consolidated in a 2015 PMC review on antimicrobial peptide wound healing and in ongoing NIH-funded cathelicidin research programs.
Researchers who apply these principles consistently report more reproducible LL-37 wound healing findings and stronger cross-model concordance.
How to Evaluate LL-37 for Wound Healing Research
Quick Answer
Strong LL-37 wound healing studies report peptide purity and source, include dose-response curves rather than single concentrations, validate findings across at least two model systems, and explicitly address the regenerative-versus-cytotoxic concentration window. Studies meeting these criteria produce the most reproducible and translatable cathelicidin data.
The volume of published cathelicidin research has expanded faster than its methodological standardization. A consistent evaluation framework helps researchers distinguish well-controlled studies from those whose conclusions outrun their data.
1. Verify Peptide Purity and Sequence
Synthetic LL-37 quality varies widely between sources. Look for studies that report HPLC purity (≥95% preferred), mass spectrometry confirmation of the 37-amino-acid sequence, and endotoxin testing. Without these, antimicrobial or regenerative effects could reflect contaminants rather than the peptide.
The U.S. Food and Drug Administration publishes general guidance on peptide characterization that maps well onto research-grade quality expectations.
2. Look for Dose-Response Data
Single-concentration studies miss LL-37’s biphasic behavior. Robust research subjects received different concentrations of peptide across at least one log range, allowing the inflection point between regenerative and cytotoxic activity to be located.
Studies utilized doses spanning roughly 0.1–50 μM in published in vitro work, with most regenerative effects clustering at 1–10 μM and cytotoxicity emerging above ~20 μM in many cell systems.
3. Check Model System Convergence
High-confidence findings replicate across in vitro scratch assays, ex vivo human skin explants, and in vivo animal models. Studies that report effects in only one system warrant cautious interpretation.
Where models diverge, the published literature generally treats ex vivo human skin and in vivo animal data as more translationally informative than monolayer cell culture findings alone.
Looking for more research on cathelicidin tissue repair? Explore Phoenix Peptide Labs’ research resource library →
4. Assess Buffer and Salt Conditions
LL-37 antimicrobial potency is sensitive to ionic strength and serum proteins. Studies that test only in low-salt buffers may overestimate activity. Look for parallel testing in physiologically relevant media.
5. Evaluate Reporting Transparency
Reproducibility hinges on full disclosure of peptide source, lot number, solvent, storage conditions, and assay timing. Studies omitting these details limit follow-on research even when their topline conclusions are interesting.
6. Weigh Clinical Trial Context Carefully
A 2014 phase I/II trial in venous leg ulcers (PMID: 24668260) remains one of the few human studies on the peptide. Early-phase data are informative but limited in size and duration; broader conclusions about therapeutic use require additional research.
Key Studies on LL-37 for Wound Healing
The table below summarizes representative cathelicidin studies across in vitro, ex vivo, in vivo, and early clinical contexts. It is not exhaustive — it is a starting reference for orienting to the published literature.
| Year | Model | Key Finding | Mechanism Implicated | Source |
|---|---|---|---|---|
| 2003 | Human chronic wound biopsies | LL-37 expression reduced in chronic ulcers vs. acute wounds | Endogenous deficiency hypothesis | PMID 12713579 |
| 2003 | Human endothelial cells, in vivo rabbit ischemia | Direct angiogenesis induction via FPRL1 | FPRL1 receptor signaling | PMID 12714512 |
| 2005 | Primary human keratinocytes | Migration stimulation via HB-EGF release | EGFR transactivation | PMID 16002740 |
| 2008 | Scratch wound assay | Dose-dependent keratinocyte migration | EGFR-mediated signaling confirmed | PMID 18408746 |
| 2014 | Phase I/II clinical trial, venous leg ulcers | Tolerability and signals of healing acceleration | Combined antimicrobial + regenerative | PMID 24668260 |
| 2015 | Comprehensive review | Anti-biofilm activity at sub-MIC concentrations | Biofilm matrix disruption | PMC4694151 |
| 2019 | Diabetic mouse excisional wound | Improved closure kinetics with topical LL-37 formulations | Multifactorial repair pathway activation | PubMed search |
Table compiled from publicly indexed PubMed and PMC records, 2003–2019. Updated June 2026.
Who Studies LL-37 in Tissue Repair Research?
LL-37 wound healing research spans academic, translational, and industrial settings, with each group bringing different questions and methodological emphasis.
The Academic Skin Biology Researcher
Studies cathelicidin signaling in keratinocyte cultures and ex vivo human skin to characterize re-epithelialization pathways. Needs high-purity peptide with documented sequence confirmation for reproducible assays.
💡 Key Consideration: Lot-to-lot consistency shapes whether scratch-assay results converge across replicates.
Read related research on antimicrobial peptide tissue repair →
The Translational Wound Researcher
Designs preclinical models bridging in vitro findings to in vivo wound closure outcomes — often in diabetic or ischemic wound contexts. Cares deeply about formulation stability against wound-bed proteases.
💡 Key Consideration: Protease resistance and delivery vehicle choice dominate translational reproducibility.
The Antimicrobial Resistance Investigator
Approaches LL-37 from the antibiotic-alternative angle, characterizing activity against multidrug-resistant clinical isolates and biofilm-embedded human bacterial pathogens.
💡 Key Consideration: Salt sensitivity and serum binding must be controlled when comparing MICs across studies.
Frequently Asked Questions
LL-37 is the only known human cathelicidin antimicrobial peptide, and research suggests it promotes wound healing through antimicrobial defense, keratinocyte migration, angiogenesis induction, and immunomodulatory signaling.
Published studies including a 2003 Journal of Investigative Dermatology paper and a 2008 keratinocyte migration study characterize these pathways. For deeper research context, explore Phoenix Peptide Labs’ research library.
Preclinical research in diabetic mouse wound models suggests LL-37 application can accelerate closure kinetics compared to vehicle controls.
Human evidence remains limited. Diabetic foot ulcers exhibit both microbial colonization and impaired keratinocyte function — two processes LL-37 acts on simultaneously — but no large controlled diabetic foot ulcer trials have established therapeutic use.
LL-37 stimulates keratinocyte migration via transactivation of the epidermal growth factor receptor, primarily through heparin-binding EGF-like growth factor release.
This mechanism was characterized in a 2008 scratch assay study and corroborated across ex vivo human skin explants. The result is faster wound closure in research models.
Yes — research indicates LL-37 induces endothelial proliferation, migration, and tube formation through FPRL1 receptor binding.
A foundational 2003 Journal of Clinical Investigation study confirmed this in vitro and in rabbit hindlimb ischemia models. Effects partially overlap with VEGF signaling but are not entirely VEGF-dependent.
Have more research questions? Browse Phoenix Peptide Labs’ research resource hub →
Most published cathelicidin studies use synthetic LL-37 at ≥95% HPLC purity with mass spectrometry sequence confirmation and documented endotoxin levels.
Lower-purity material risks confounding regenerative or antimicrobial readouts with effects from impurities or truncated peptide fragments. Certificates of analysis should accompany any peptide used in publishable research.
Lyophilized LL-37 is typically stored at −20 °C or below, and reconstituted aliquots should be used promptly or frozen at −80 °C to minimize freeze-thaw cycles.
Activity is sensitive to repeated freeze-thaw, oxidation, and adsorption to plastic surfaces — all of which can erode apparent potency across an experimental timeline. Detailed handling notes belong in every research study’s methods section.
No — LL-37 is not approved by the U.S. Food and Drug Administration for human therapeutic, diagnostic, or veterinary use.
All material discussed on this page is for research use only. Early-phase clinical investigation has been conducted (e.g., a 2014 phase I/II venous leg ulcer trial), but this does not constitute approval or therapeutic endorsement.
Key limitations include the peptide’s biphasic concentration-response curve, protease degradation in chronic wound fluid, salt and serum sensitivity, and limited large human trial data.
Beyond its antimicrobial activity, LL-37 has both pro- and anti-inflammatory profiles depending on context, which complicates clean mechanistic interpretation. For sourcing or documentation questions, contact our team via our contact page.